|
a |
|
b/html_files/28057913.html |
|
|
1 |
|
|
|
2 |
<!DOCTYPE html> |
|
|
3 |
<html> |
|
|
4 |
<head> |
|
|
5 |
<meta charset="utf-8"> |
|
|
6 |
<title>28057913 Visualization</title> |
|
|
7 |
</head> |
|
|
8 |
<body> |
|
|
9 |
<h1>28057913 Visualization</h1> |
|
|
10 |
<p><a href="main.html">Back to Main Page</a></p> |
|
|
11 |
<div class="entities" style="line-height: 2.5; direction: ltr">A |
|
|
12 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
13 |
53 |
|
|
14 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
15 |
</mark> |
|
|
16 |
- |
|
|
17 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
18 |
year |
|
|
19 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
20 |
</mark> |
|
|
21 |
- |
|
|
22 |
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
23 |
old |
|
|
24 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span> |
|
|
25 |
</mark> |
|
|
26 |
|
|
|
27 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
28 |
woman |
|
|
29 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span> |
|
|
30 |
</mark> |
|
|
31 |
|
|
|
32 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
33 |
presented |
|
|
34 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
|
|
35 |
</mark> |
|
|
36 |
to our |
|
|
37 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
38 |
institution |
|
|
39 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Nonbiological_location</span> |
|
|
40 |
</mark> |
|
|
41 |
with |
|
|
42 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
43 |
progressive |
|
|
44 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
45 |
</mark> |
|
|
46 |
|
|
|
47 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
48 |
abdominal |
|
|
49 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
50 |
</mark> |
|
|
51 |
|
|
|
52 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
53 |
distention |
|
|
54 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
55 |
</mark> |
|
|
56 |
and |
|
|
57 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
58 |
irregular |
|
|
59 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
60 |
</mark> |
|
|
61 |
|
|
|
62 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
63 |
vaginal |
|
|
64 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
65 |
</mark> |
|
|
66 |
|
|
|
67 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
68 |
bleeding |
|
|
69 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
70 |
</mark> |
|
|
71 |
of |
|
|
72 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
73 |
several |
|
|
74 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
75 |
</mark> |
|
|
76 |
|
|
|
77 |
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
78 |
weeks |
|
|
79 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span> |
|
|
80 |
</mark> |
|
|
81 |
’ duration.</br>A |
|
|
82 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
83 |
contrast |
|
|
84 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
85 |
</mark> |
|
|
86 |
|
|
|
87 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
88 |
CT |
|
|
89 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
90 |
</mark> |
|
|
91 |
|
|
|
92 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
93 |
abdomen |
|
|
94 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
95 |
</mark> |
|
|
96 |
and |
|
|
97 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
98 |
pelvis |
|
|
99 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
100 |
</mark> |
|
|
101 |
revealed an |
|
|
102 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
103 |
ill |
|
|
104 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
105 |
</mark> |
|
|
106 |
- |
|
|
107 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
108 |
defined |
|
|
109 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
110 |
</mark> |
|
|
111 |
, |
|
|
112 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
113 |
irregular |
|
|
114 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
115 |
</mark> |
|
|
116 |
|
|
|
117 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
118 |
mass |
|
|
119 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
120 |
</mark> |
|
|
121 |
in the |
|
|
122 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
123 |
lower |
|
|
124 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
125 |
</mark> |
|
|
126 |
|
|
|
127 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
128 |
uterine |
|
|
129 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
130 |
</mark> |
|
|
131 |
/ |
|
|
132 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
133 |
cervical |
|
|
134 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
135 |
</mark> |
|
|
136 |
|
|
|
137 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
138 |
region |
|
|
139 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
140 |
</mark> |
|
|
141 |
(Figure 1).</br>There were |
|
|
142 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
143 |
multiple |
|
|
144 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
145 |
</mark> |
|
|
146 |
|
|
|
147 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
148 |
peritoneal |
|
|
149 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
150 |
</mark> |
|
|
151 |
and |
|
|
152 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
153 |
omental |
|
|
154 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
155 |
</mark> |
|
|
156 |
|
|
|
157 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
158 |
masses |
|
|
159 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
160 |
</mark> |
|
|
161 |
, |
|
|
162 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
163 |
enlarged |
|
|
164 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
165 |
</mark> |
|
|
166 |
|
|
|
167 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
168 |
pelvic |
|
|
169 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
170 |
</mark> |
|
|
171 |
and |
|
|
172 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
173 |
paraaortic |
|
|
174 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
175 |
</mark> |
|
|
176 |
|
|
|
177 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
178 |
lymph |
|
|
179 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
180 |
</mark> |
|
|
181 |
|
|
|
182 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
183 |
nodes |
|
|
184 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
185 |
</mark> |
|
|
186 |
, and |
|
|
187 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
188 |
large |
|
|
189 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
190 |
</mark> |
|
|
191 |
- |
|
|
192 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
193 |
volume |
|
|
194 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
195 |
</mark> |
|
|
196 |
|
|
|
197 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
198 |
ascites |
|
|
199 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
200 |
</mark> |
|
|
201 |
.</br>The initial |
|
|
202 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
203 |
CBC |
|
|
204 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
205 |
</mark> |
|
|
206 |
was significant for |
|
|
207 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
208 |
hemoglobin |
|
|
209 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
210 |
</mark> |
|
|
211 |
of |
|
|
212 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
213 |
9.2 |
|
|
214 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
215 |
</mark> |
|
|
216 |
|
|
|
217 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
218 |
g/dL |
|
|
219 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
220 |
</mark> |
|
|
221 |
, |
|
|
222 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
223 |
leukocytosis |
|
|
224 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
225 |
</mark> |
|
|
226 |
of |
|
|
227 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
228 |
36 |
|
|
229 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
230 |
</mark> |
|
|
231 |
|
|
|
232 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
233 |
790 |
|
|
234 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
235 |
</mark> |
|
|
236 |
|
|
|
237 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
238 |
per |
|
|
239 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
240 |
</mark> |
|
|
241 |
|
|
|
242 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
243 |
microliter |
|
|
244 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
245 |
</mark> |
|
|
246 |
, and |
|
|
247 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
248 |
thrombocytosis |
|
|
249 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
250 |
</mark> |
|
|
251 |
of |
|
|
252 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
253 |
625 |
|
|
254 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
255 |
</mark> |
|
|
256 |
|
|
|
257 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
258 |
000 |
|
|
259 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
260 |
</mark> |
|
|
261 |
|
|
|
262 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
263 |
per |
|
|
264 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
265 |
</mark> |
|
|
266 |
|
|
|
267 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
268 |
microliter |
|
|
269 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
270 |
</mark> |
|
|
271 |
.</br> |
|
|
272 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
273 |
Serum |
|
|
274 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
275 |
</mark> |
|
|
276 |
|
|
|
277 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
278 |
calcium |
|
|
279 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
280 |
</mark> |
|
|
281 |
was |
|
|
282 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
283 |
elevated |
|
|
284 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
285 |
</mark> |
|
|
286 |
at |
|
|
287 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
288 |
13.1 |
|
|
289 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
290 |
</mark> |
|
|
291 |
mg/dL.</br> |
|
|
292 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
293 |
BUN |
|
|
294 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
295 |
</mark> |
|
|
296 |
and |
|
|
297 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
298 |
creatinine |
|
|
299 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
300 |
</mark> |
|
|
301 |
were |
|
|
302 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
303 |
within |
|
|
304 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
305 |
</mark> |
|
|
306 |
|
|
|
307 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
308 |
normal |
|
|
309 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
310 |
</mark> |
|
|
311 |
|
|
|
312 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
313 |
limits |
|
|
314 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
315 |
</mark> |
|
|
316 |
.</br> |
|
|
317 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
318 |
Hepatic |
|
|
319 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
320 |
</mark> |
|
|
321 |
|
|
|
322 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
323 |
function |
|
|
324 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
325 |
</mark> |
|
|
326 |
was |
|
|
327 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
328 |
within |
|
|
329 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
330 |
</mark> |
|
|
331 |
|
|
|
332 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
333 |
normal |
|
|
334 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
335 |
</mark> |
|
|
336 |
|
|
|
337 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
338 |
limits |
|
|
339 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
340 |
</mark> |
|
|
341 |
.</br>A |
|
|
342 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
343 |
pelvic |
|
|
344 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
345 |
</mark> |
|
|
346 |
|
|
|
347 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
348 |
exam |
|
|
349 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
350 |
</mark> |
|
|
351 |
revealed a |
|
|
352 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
353 |
fungating |
|
|
354 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
355 |
</mark> |
|
|
356 |
|
|
|
357 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
358 |
vaginal |
|
|
359 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
360 |
</mark> |
|
|
361 |
|
|
|
362 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
363 |
mass |
|
|
364 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
365 |
</mark> |
|
|
366 |
.</br>The patient underwent |
|
|
367 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
368 |
biopsies |
|
|
369 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
370 |
</mark> |
|
|
371 |
of the |
|
|
372 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
373 |
endometrium |
|
|
374 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
375 |
</mark> |
|
|
376 |
and the |
|
|
377 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
378 |
vaginal |
|
|
379 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
380 |
</mark> |
|
|
381 |
|
|
|
382 |
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
383 |
mass |
|
|
384 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span> |
|
|
385 |
</mark> |
|
|
386 |
, which revealed a |
|
|
387 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
388 |
high |
|
|
389 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Severity</span> |
|
|
390 |
</mark> |
|
|
391 |
- |
|
|
392 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
393 |
grade |
|
|
394 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Severity</span> |
|
|
395 |
</mark> |
|
|
396 |
|
|
|
397 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
398 |
tumor |
|
|
399 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
400 |
</mark> |
|
|
401 |
with |
|
|
402 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
403 |
predominantly |
|
|
404 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
405 |
</mark> |
|
|
406 |
|
|
|
407 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
408 |
oval |
|
|
409 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
410 |
</mark> |
|
|
411 |
- |
|
|
412 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
413 |
shaped |
|
|
414 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
415 |
</mark> |
|
|
416 |
|
|
|
417 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
418 |
cells |
|
|
419 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
420 |
</mark> |
|
|
421 |
.</br> |
|
|
422 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
423 |
Immunohistochemical |
|
|
424 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
425 |
</mark> |
|
|
426 |
|
|
|
427 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
428 |
staining |
|
|
429 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
430 |
</mark> |
|
|
431 |
was |
|
|
432 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
433 |
positive |
|
|
434 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
435 |
</mark> |
|
|
436 |
for |
|
|
437 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
438 |
vimentin |
|
|
439 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
440 |
</mark> |
|
|
441 |
, |
|
|
442 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
443 |
CD10 |
|
|
444 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
445 |
</mark> |
|
|
446 |
, and |
|
|
447 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
448 |
cyclin |
|
|
449 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
450 |
</mark> |
|
|
451 |
|
|
|
452 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
453 |
D1 |
|
|
454 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
455 |
</mark> |
|
|
456 |
, consistent with a diagnosis of |
|
|
457 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
458 |
high |
|
|
459 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Severity</span> |
|
|
460 |
</mark> |
|
|
461 |
- |
|
|
462 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
463 |
grade |
|
|
464 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Severity</span> |
|
|
465 |
</mark> |
|
|
466 |
|
|
|
467 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
468 |
endometrial |
|
|
469 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
470 |
</mark> |
|
|
471 |
|
|
|
472 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
473 |
stromal |
|
|
474 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
475 |
</mark> |
|
|
476 |
|
|
|
477 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
478 |
sarcoma |
|
|
479 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
480 |
</mark> |
|
|
481 |
(Figure 2).</br>The |
|
|
482 |
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
483 |
tumor |
|
|
484 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span> |
|
|
485 |
</mark> |
|
|
486 |
was |
|
|
487 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
488 |
negative |
|
|
489 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
490 |
</mark> |
|
|
491 |
for |
|
|
492 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
493 |
ER |
|
|
494 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
495 |
</mark> |
|
|
496 |
, with |
|
|
497 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
498 |
rare |
|
|
499 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
500 |
</mark> |
|
|
501 |
|
|
|
502 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
503 |
cells |
|
|
504 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
505 |
</mark> |
|
|
506 |
|
|
|
507 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
508 |
positive |
|
|
509 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
510 |
</mark> |
|
|
511 |
for |
|
|
512 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
513 |
PR |
|
|
514 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
515 |
</mark> |
|
|
516 |
.</br>Although |
|
|
517 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
518 |
immunohistochemical |
|
|
519 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
520 |
</mark> |
|
|
521 |
|
|
|
522 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
523 |
staining |
|
|
524 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
525 |
</mark> |
|
|
526 |
for |
|
|
527 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
528 |
cytokeratins |
|
|
529 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
530 |
</mark> |
|
|
531 |
was |
|
|
532 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
533 |
negative |
|
|
534 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
535 |
</mark> |
|
|
536 |
, a |
|
|
537 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
538 |
biphasic |
|
|
539 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
540 |
</mark> |
|
|
541 |
|
|
|
542 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
543 |
component |
|
|
544 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
545 |
</mark> |
|
|
546 |
could not be entirely ruled out given the small size of the biopsy specimen relative to the tumor.</br>The patient’s |
|
|
547 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
548 |
Ca125 |
|
|
549 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
550 |
</mark> |
|
|
551 |
was markedly |
|
|
552 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
553 |
elevated |
|
|
554 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
555 |
</mark> |
|
|
556 |
at |
|
|
557 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
558 |
1624 |
|
|
559 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
560 |
</mark> |
|
|
561 |
|
|
|
562 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
563 |
U/mL |
|
|
564 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
565 |
</mark> |
|
|
566 |
(nl ≤34).</br> |
|
|
567 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
568 |
Contrast |
|
|
569 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
570 |
</mark> |
|
|
571 |
|
|
|
572 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
573 |
CT |
|
|
574 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
575 |
</mark> |
|
|
576 |
|
|
|
577 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
578 |
chest |
|
|
579 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
580 |
</mark> |
|
|
581 |
revealed a |
|
|
582 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
583 |
right |
|
|
584 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
585 |
</mark> |
|
|
586 |
- |
|
|
587 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
588 |
sided |
|
|
589 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
590 |
</mark> |
|
|
591 |
|
|
|
592 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
593 |
pleural |
|
|
594 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
595 |
</mark> |
|
|
596 |
|
|
|
597 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
598 |
effusion |
|
|
599 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
600 |
</mark> |
|
|
601 |
but no |
|
|
602 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
603 |
suspicious |
|
|
604 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
605 |
</mark> |
|
|
606 |
|
|
|
607 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
608 |
nodules |
|
|
609 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
610 |
</mark> |
|
|
611 |
or |
|
|
612 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
613 |
lymphadenopathy |
|
|
614 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
615 |
</mark> |
|
|
616 |
.</br>The patient was deemed to have |
|
|
617 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
618 |
operable |
|
|
619 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
620 |
</mark> |
|
|
621 |
|
|
|
622 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
623 |
disease |
|
|
624 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
625 |
</mark> |
|
|
626 |
and was scheduled for |
|
|
627 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
628 |
debulking |
|
|
629 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
630 |
</mark> |
|
|
631 |
|
|
|
632 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
633 |
surgery |
|
|
634 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
635 |
</mark> |
|
|
636 |
.</br>However, preoperative |
|
|
637 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
638 |
laboratory |
|
|
639 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
640 |
</mark> |
|
|
641 |
|
|
|
642 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
643 |
studies |
|
|
644 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
645 |
</mark> |
|
|
646 |
showed that her |
|
|
647 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
648 |
serum |
|
|
649 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
650 |
</mark> |
|
|
651 |
|
|
|
652 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
653 |
calcium |
|
|
654 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
655 |
</mark> |
|
|
656 |
had further |
|
|
657 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
658 |
increased |
|
|
659 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
660 |
</mark> |
|
|
661 |
to |
|
|
662 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
663 |
19.2 |
|
|
664 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
665 |
</mark> |
|
|
666 |
mg/dL.</br>She had also developed evidence of |
|
|
667 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
668 |
acute |
|
|
669 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
670 |
</mark> |
|
|
671 |
|
|
|
672 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
673 |
kidney |
|
|
674 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
675 |
</mark> |
|
|
676 |
|
|
|
677 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
678 |
injury |
|
|
679 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
680 |
</mark> |
|
|
681 |
, with her |
|
|
682 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
683 |
BUN |
|
|
684 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
685 |
</mark> |
|
|
686 |
|
|
|
687 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
688 |
rising |
|
|
689 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
690 |
</mark> |
|
|
691 |
to |
|
|
692 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
693 |
37 |
|
|
694 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
695 |
</mark> |
|
|
696 |
|
|
|
697 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
698 |
mg/dL |
|
|
699 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
700 |
</mark> |
|
|
701 |
and |
|
|
702 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
703 |
creatinine |
|
|
704 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
705 |
</mark> |
|
|
706 |
to |
|
|
707 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
708 |
1.81 |
|
|
709 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
710 |
</mark> |
|
|
711 |
mg/dL.</br>On |
|
|
712 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
713 |
physical |
|
|
714 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
715 |
</mark> |
|
|
716 |
|
|
|
717 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
718 |
exam |
|
|
719 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
720 |
</mark> |
|
|
721 |
, she was noted to be |
|
|
722 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
723 |
lethargic |
|
|
724 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
725 |
</mark> |
|
|
726 |
, with |
|
|
727 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
728 |
dry |
|
|
729 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
730 |
</mark> |
|
|
731 |
|
|
|
732 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
733 |
mucous |
|
|
734 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
735 |
</mark> |
|
|
736 |
|
|
|
737 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
738 |
membranes |
|
|
739 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
740 |
</mark> |
|
|
741 |
.</br>The |
|
|
742 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
743 |
surgery |
|
|
744 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
745 |
</mark> |
|
|
746 |
was |
|
|
747 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
748 |
cancelled |
|
|
749 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span> |
|
|
750 |
</mark> |
|
|
751 |
due to the patient’s |
|
|
752 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
753 |
medical |
|
|
754 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
755 |
</mark> |
|
|
756 |
|
|
|
757 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
758 |
instability |
|
|
759 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
760 |
</mark> |
|
|
761 |
.</br>Further workup revealed an |
|
|
762 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
763 |
elevated |
|
|
764 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
765 |
</mark> |
|
|
766 |
|
|
|
767 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
768 |
PTHrP |
|
|
769 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
770 |
</mark> |
|
|
771 |
of |
|
|
772 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
773 |
301 |
|
|
774 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
775 |
</mark> |
|
|
776 |
|
|
|
777 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
778 |
pg/mL |
|
|
779 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
780 |
</mark> |
|
|
781 |
(nl 14–27), a |
|
|
782 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
783 |
depressed |
|
|
784 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
785 |
</mark> |
|
|
786 |
|
|
|
787 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
788 |
PTH |
|
|
789 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
790 |
</mark> |
|
|
791 |
level of |
|
|
792 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
793 |
3 |
|
|
794 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
795 |
</mark> |
|
|
796 |
|
|
|
797 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
798 |
pg/mL |
|
|
799 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
800 |
</mark> |
|
|
801 |
(nl 15–65), and a |
|
|
802 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
803 |
depressed |
|
|
804 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
805 |
</mark> |
|
|
806 |
|
|
|
807 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
808 |
25 |
|
|
809 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
810 |
</mark> |
|
|
811 |
- |
|
|
812 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
813 |
OH |
|
|
814 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
815 |
</mark> |
|
|
816 |
|
|
|
817 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
818 |
vitamin |
|
|
819 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
820 |
</mark> |
|
|
821 |
|
|
|
822 |
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
823 |
D |
|
|
824 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span> |
|
|
825 |
</mark> |
|
|
826 |
level of |
|
|
827 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
828 |
16 |
|
|
829 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
830 |
</mark> |
|
|
831 |
|
|
|
832 |
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
833 |
ng/mL |
|
|
834 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span> |
|
|
835 |
</mark> |
|
|
836 |
(nl 30–100), consistent with |
|
|
837 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
838 |
humoral |
|
|
839 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
840 |
</mark> |
|
|
841 |
|
|
|
842 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
843 |
hypercalcemia |
|
|
844 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
845 |
</mark> |
|
|
846 |
|
|
|
847 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
848 |
of |
|
|
849 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
850 |
</mark> |
|
|
851 |
|
|
|
852 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
853 |
malignancy |
|
|
854 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
855 |
</mark> |
|
|
856 |
.</br>The patient was treated with |
|
|
857 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
858 |
pamidronate |
|
|
859 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
860 |
</mark> |
|
|
861 |
, |
|
|
862 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
863 |
calcitonin |
|
|
864 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
865 |
</mark> |
|
|
866 |
, and |
|
|
867 |
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
868 |
intravenous |
|
|
869 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span> |
|
|
870 |
</mark> |
|
|
871 |
|
|
|
872 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
873 |
fluids |
|
|
874 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
875 |
</mark> |
|
|
876 |
.</br>She eventually required |
|
|
877 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
878 |
temporary |
|
|
879 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
880 |
</mark> |
|
|
881 |
|
|
|
882 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
883 |
hemodialysis |
|
|
884 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
885 |
</mark> |
|
|
886 |
and |
|
|
887 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
888 |
denosumab |
|
|
889 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
890 |
</mark> |
|
|
891 |
for |
|
|
892 |
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
893 |
refractory |
|
|
894 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span> |
|
|
895 |
</mark> |
|
|
896 |
|
|
|
897 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
898 |
hypercalcemia |
|
|
899 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
900 |
</mark> |
|
|
901 |
.</br>The patient improved with regard to her |
|
|
902 |
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
903 |
electrolyte |
|
|
904 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span> |
|
|
905 |
</mark> |
|
|
906 |
|
|
|
907 |
<mark class="entity" style="background: #e3b5a4; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
908 |
abnormalities |
|
|
909 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Coreference</span> |
|
|
910 |
</mark> |
|
|
911 |
.</br>Given the extent of her disease, she was planned for neoadjuvant |
|
|
912 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
913 |
chemotherapy |
|
|
914 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
915 |
</mark> |
|
|
916 |
followed by |
|
|
917 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
918 |
surgery |
|
|
919 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
920 |
</mark> |
|
|
921 |
if a good response was achieved.</br>She was started on a regimen of |
|
|
922 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
923 |
carboplatin |
|
|
924 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
925 |
</mark> |
|
|
926 |
and |
|
|
927 |
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
928 |
paclitaxel |
|
|
929 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span> |
|
|
930 |
</mark> |
|
|
931 |
, which she received for |
|
|
932 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
933 |
3 |
|
|
934 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
935 |
</mark> |
|
|
936 |
|
|
|
937 |
<mark class="entity" style="background: #b9e8d8; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
938 |
cycles |
|
|
939 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Dosage</span> |
|
|
940 |
</mark> |
|
|
941 |
.</br>She also had palliative |
|
|
942 |
<mark class="entity" style="background: #e6ccb2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
943 |
radiation |
|
|
944 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Therapeutic_procedure</span> |
|
|
945 |
</mark> |
|
|
946 |
to the |
|
|
947 |
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
948 |
uterus |
|
|
949 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span> |
|
|
950 |
</mark> |
|
|
951 |
to control |
|
|
952 |
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
953 |
bleeding |
|
|
954 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span> |
|
|
955 |
</mark> |
|
|
956 |
.</br>However, her disease failed to respond significantly to chemotherapy, and she ultimately |
|
|
957 |
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
958 |
died |
|
|
959 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Outcome</span> |
|
|
960 |
</mark> |
|
|
961 |
from |
|
|
962 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
963 |
complications |
|
|
964 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
965 |
</mark> |
|
|
966 |
|
|
|
967 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
968 |
of |
|
|
969 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
970 |
</mark> |
|
|
971 |
|
|
|
972 |
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;"> |
|
|
973 |
malignancy |
|
|
974 |
<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span> |
|
|
975 |
</mark> |
|
|
976 |
.</br></div> |
|
|
977 |
</body> |
|
|
978 |
</html> |
|
|
979 |
|